IMNM•Immunome said its experimental antibody-drug conjugate IM-1021 showed a 53% response rate in an early-stage trial in advanced B-cell lymphomas. The company will present initial Phase 1 results at ASH on December 14, 2026.
IM-1021 produced complete and partial responses in heavily pretreated patients, with responses across all tested dose levels. Clinical activity included patients whose disease had progressed after T-cell redirecting therapies. Serious treatment-emergent adverse events included low neutrophil counts, the most common severe event; dose optimization across multiple regimens is ongoing, with updated results planned for the meeting.
